Episode
FDA Approval: Zidesamtinib and ROS1 NSCLC
- Podcast
- Lung Cancer Considered
- Published
- Jul 28, 2026
- Duration seconds
- 1441
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/fda-approval-zidesamtinib-and-ros1-nsclc/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/fda-approval-zidesamtinib-and-ros1-nsclc.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain